九州通医药集团股份有限公司（以下简称"公司"）聘请中审众环会计师事务 所（特殊普通合伙）（以下简称"中审众环"）作为公司2024年度财务及内部控制审 计机构。根据《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交易 所上市公司自律监管指引第1号—规范运作》等有关规定，公司财务与审计委员会本 着勤勉尽责的原则，恪尽职守，认真履职。现将会计师事务所2024年度履职情况及 财务与审计委员会履行监督职责情况汇报如下： 1、基本信息 中审众环始创于1987年，是全国首批取得国家批准具有从事证券、期货相关 业务资格及金融业务审计资格的大型会计师事务所之一。根据财政部、证监会发 布的从事证券服务业务会计师事务所备案名单，具备股份有限公司发行股份、债 券审计机构的资格。2013年11月，按照国家财政部等有关要求转制为特殊普通合 伙制。注册地址为湖北省武汉市武昌区水果湖街道中北路166号长江产业大厦 17-18楼。 2、人员信息 （1）首席合伙人：石文先 （2）2024年末合伙人数量216人、注册会计师数量1,304人、签署过证券服 务业务审计报告的注册会计师人数723人。 3、业务规模 2024年经审计总收入217, ...

(一)《中华人民共和国公司法》关于董事任职资格的规定; (二)《中华人民共和国公务员法》关于公务员兼任职务的规定(如 适用): (三)中国证监会《上市公司独立董事管理办法》、上海证券交易 所自律监管规则以及公司章程有关独立董事任职资格和条件的相关规 定; (四)中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退(离)休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定(如适用); 独立董事提名人声明与承诺 提名人九州通医药集团股份有限公司董事会,现提名王瑛为九州 通医药集团股份有限公司第六届董事会独立董事候选人,并已充分了 解被提名人职业、学历、职称、详细的工作经历、全部兼职、有无重 大失信等不良记录等情况。被提名人已同意出任九州通医药集团股份 有限公司第六届董事会独立董事候选人(参见该独立董事候选人声明)。 提名人认为,被提名人具备独立董事任职资格,与九州通医药集团股 份有限公司之间不存在任何影响其独立性的关系,具体声明并承诺如 下: 一、被提名人具备上市公司运作的基本知识,熟悉相关法律、行 政法规、规章及其他规范性文件,具有5年以上法律、经济、会计、 财务、管理或者其他履行独立董事 ...

公司代码：600998 公司简称：九州通 九州通医药集团股份有限公司 2024 年年度股东会 会议资料 2025 年 5 月 九州通医药集团股份有限公司 2024 年年度股东会会议资料 1 九州通医药集团股份有限公司 2024 年年度股东会会议资料 九州通医药集团股份有限公司 2024 年年度股东会议程 一、会议召开形式： 本次会议采用现场投票、网络投票相结合的形式 二、会议时间： 1、现场会议召开时间：2025 年 5 月 23 日（周五）上午 10:00 2、网络投票时间：2025 年 5 月 23 日（周五）9:15-9:25，9:30-11:30，13:00-15:00 三、会议召开地点：武汉市汉阳区龙兴西街 5 号九州通总部大厦会议室 公司董事：刘长云、刘兆年、龚翼华、刘登攀、刘义常、贺威、王琦、 吴雪松、曾湘泉、汤谷良、艾华、陆银娣 列席人员： 公司监事：许应政、林新扬、刘庆鑫 公司高级管理人员：龚翼华、刘义常、贺威、陈卫俊、许志君、郭磊、 王启兵、杨聂、杨菊美、刘志峰、张青松、夏晓益、全铭、苏熙凌 见证律师：北京海润天睿律师事务所的律师 四、会议主持人：刘长云先生 五、与会人员： 公司股东 （一 ...

证券代码：600998 证券简称：九州通 公告编号：2025-028 九州通医药集团股份有限公司 关于召开2024年年度股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 23 日 至2025 年 5 月 23 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联网 投票平台的投票时间为股东会召开当日的 9:15-15:00。 (四)现场会议召开的日期、时间和地点 一、 召开会议的基本情况 召开的日期时间：2025 年 5 月 23 日 10 点 00 分 召开地点：武汉市汉阳区龙兴西街 5 号九州通总部大厦会议室 (一)股东会类型和届次 股东会召开日期：2025年5月23日 本次股东会涉及优先股表决议案 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系 统 (二)股东会召集 ...

公司已经建立了较为完善的内部控制制度，符合国家相关法律法规要求以及公 司生产经营管理实际需要，并能够得到有效的执行；公司内部控制体系的建立和有 效执行对公司经营管理的各个环节起到了较好的风险防范和控制作用，保护了公司 的资产安全完整，维护了公司及股东的利益。公司内部控制评价报告真实、客观地 反映了公司内部控制制度的建设和运行情况。 九州通医药集团股份有限公司监事会 2025 年 4 月 29 日 九州通医药集团股份有限公司监事会关于 第六届监事会第十二次会议相关事项的核查意见 根据《公司法》《证券法》《上海证券交易所股票上市规则》等有关法律法规、 规范性文件以及《公司章程》的规定，九州通医药集团股份有限公司（以下简称"公 司"）监事会对内部控制评价报告进行核查，并发表意见如下： ...

经过审议并表决，本次会议通过了以下议案： 一、《关于公司 2024 年度监事会工作报告的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 该议案尚需提交公司股东会审议批准。 详见公司同日披露的《九州通 2024 年度监事会工作报告》。 证券代码：600998 证券简称：九州通 公告编号：临 2025-024 九州通医药集团股份有限公司 第六届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 4 月 26 日，九州通医药集团股份有限公司（以下简称"九州通"或 "公司"）召开第六届监事会第十二次会议，本次会议以现场结合通讯方式召开， 根据公司《监事会议事规则》的相关规定，会议通知于 2025 年 4 月 7 日以电话、 邮件、微信等方式通知全体监事。本次会议应到监事 3 人，实到 3 人，会议由监 事会主席许应政先生主持。本次会议的召集和召开程序符合《公司法》及《公司 章程》等相关规定。 二、《关于公司 2024 年度财务报告的议案》 表决结果：同意 3 票，反对 0 票，弃权 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 42.02 billion, an increase of 3.82% compared to CNY 40.47 billion in the same period last year[4]. - Net profit attributable to shareholders increased by 80.38% to CNY 969.86 million from CNY 537.68 million year-on-year, primarily due to the successful issuance of public REITs in pharmaceutical warehousing and logistics[5]. - Basic and diluted earnings per share rose by 72.73% to CNY 0.19 from CNY 0.11 in the previous year[4]. - The weighted average return on equity increased by 1.43 percentage points to 3.65% compared to 2.22% in the previous year[4]. - The company reported a net profit for Q1 2025 reached CNY 1,013,884,074.60, a significant increase of 86.8% compared to CNY 542,165,921.17 in Q1 2024[26]. - The operating profit for Q1 2025 was CNY 1,274,549,197.37, compared to CNY 665,397,152.22 in Q1 2024, indicating an increase of 91.6%[26]. - The total comprehensive income for Q1 2025 was CNY 1,009,835,379.52, compared to CNY 550,367,460.58 in Q1 2024, reflecting an increase of 83.2%[27]. - The company reported a total profit of CNY 1,275,377,036.64 for Q1 2025, significantly higher than CNY 661,813,519.47 in Q1 2024, an increase of 92.5%[26]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 108.88 billion, reflecting a growth of 6.33% from CNY 102.40 billion at the end of the previous year[5]. - Total liabilities increased to ¥74,104,148,287.75 from ¥68,802,838,471.51, representing an increase of 7.4%[22]. - The company's equity attributable to shareholders rose to ¥28,229,695,580.44, up from ¥27,243,192,189.04, reflecting a growth of 3.6%[23]. - Short-term borrowings increased significantly to ¥12,780,938,781.11 from ¥9,935,748,652.23, indicating a rise of 28.0%[22]. Cash Flow - The net cash flow from operating activities was negative CNY 3.33 billion, an improvement of 8.91% from negative CNY 3.65 billion in the same period last year[4]. - The company reported a net cash outflow from operating activities of CNY -3,327,926,818.37 in Q1 2025, an improvement from CNY -3,653,621,916.00 in Q1 2024[29]. - Cash and cash equivalents at the end of Q1 2025 totaled CNY 8,415,373,194.19, compared to CNY 6,329,431,890.60 at the end of Q1 2024, marking an increase of 33.0%[30]. - Investment activities generated a net cash inflow of CNY 1,789,864,045.80 in Q1 2025, compared to a net outflow of CNY -328,319,434.32 in Q1 2024[29]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 47,926, with the top ten shareholders holding a combined 66.32% of the shares[10]. - The top ten shareholders include major entities such as Zhongyin Financial Asset Investment Co., holding 25.14% of preferred shares, and ICBC Financial Asset Investment Co., holding 20.78%[14]. Strategic Initiatives - The company plans to continue expanding its pharmaceutical warehousing and logistics infrastructure through public REITs, enhancing its operational efficiency and profitability[5]. - The company is actively expanding its market presence and enhancing its logistics capabilities through strategic initiatives and partnerships in the pharmaceutical sector[17]. - The company plans to focus on market expansion and new product development in the upcoming quarters to drive future growth[25]. Research and Development - Research and development expenses decreased to ¥36,128,402.16 in Q1 2025 from ¥44,253,731.42 in Q1 2024, showing a decline of 18.4%[25]. Other Financial Metrics - Non-recurring gains and losses totaled CNY 462.70 million, with significant contributions from asset disposals and government subsidies[7]. - The company redeemed financial products, leading to a 93.59% decrease in trading financial assets[9]. - The company achieved a diluted earnings per share of CNY 0.19 in Q1 2025, up from CNY 0.11 in Q1 2024, representing a growth of 72.7%[27]. - Total revenue from sales of goods and services in Q1 2025 was CNY 35,599,953,547.22, up from CNY 32,587,421,059.88 in Q1 2024, reflecting a growth of 6.2%[28].

Financial Performance - The company's total revenue reached CNY 151.81 billion, representing a year-on-year growth of 1.11% despite a high base from the previous year[6]. - Net profit attributable to shareholders was CNY 2.507 billion, an increase of 15.33% year-on-year[6]. - The net profit attributable to shareholders increased by 15.33% to ¥2.51 billion, up from ¥2.17 billion in the previous year[44]. - The net cash flow from operating activities was ¥3.08 billion, a decrease of 35.07% compared to ¥4.75 billion in 2023[44]. - The company reported a 2.58% year-over-year increase in sales revenue, with a 39.88% increase in net profit attributable to shareholders after excluding non-recurring gains and losses[48]. - The basic earnings per share for 2024 was ¥0.50, up 16.28% from ¥0.43 in 2023[45]. - The total cash dividend for 2024 is projected to be 1.27 billion yuan, accounting for 50.47% of the net profit attributable to shareholders[26]. Business Expansion and Strategy - The company plans to expand its retail network to over 33,500 stores by 2025, transitioning from rapid expansion to improving operational quality[17]. - The company aims for new product sales to account for 20% of total revenue and 50% of gross profit by 2025, focusing on high-value products that align with strategic needs[17]. - Jointown plans to expand its market presence by entering three new provinces in the upcoming fiscal year[36]. - The company targets to develop over 2,000 member stores under the "Nine Medical Clinics" initiative by 2025, enhancing product variety and providing digital operational services[18]. - The company is exploring potential acquisitions to strengthen its supply chain and distribution network[36]. Research and Development - R&D investment reached CNY 346 million, reflecting a year-on-year increase of 24.32%[14]. - The company invested 200 million RMB in R&D for new drug development, focusing on oncology and chronic diseases[36]. - The company invested 346 million RMB in R&D, a year-on-year increase of 24.32%, with a total of 1,555 R&D personnel[96]. - A total of 264 high-end professionals were recruited in the reporting period, with plans to recruit an additional 300 high-potential talents by 2025[62]. Digital Transformation and Technology - The digital transformation initiatives have improved operational efficiency and reduced costs, with the orthopedic service platform covering over 3.2 million industry terminals[14]. - The company has implemented 47 digital and AI projects, collaborating with Alibaba Cloud and Tencent Cloud, enhancing operational efficiency and competitiveness[62]. - The AI medical service application demonstration base project, co-built with Wuhan Artificial Intelligence Research Institute, can automatically identify and manage over 2,000 types of medical devices, achieving a 30-fold efficiency improvement and 99.9% accuracy[139]. - The company has launched a comprehensive AI application in logistics, including AI-driven warehouse picking and smart logistics solutions, significantly improving operational efficiency[129]. Social Responsibility and Community Engagement - The company actively participated in social responsibility initiatives, contributing over CNY 18.2 million to public welfare[10]. - The company donated a total of 1 million yuan in materials and funds to support disaster relief efforts in Gansu and Hunan[142]. - The company received the "Special Contribution Award" from the Hubei Red Cross Society for its outstanding contributions to social responsibility[144]. Market Trends and Regulatory Environment - The implementation of the medical insurance fund prepayment and instant settlement policies will significantly improve cash flow for pharmaceutical distribution companies, enhancing their receivables from medical institutions[148][152]. - The ongoing deepening of volume-based procurement will create development opportunities for the company's CSO and innovative drug collaborations[154]. - The NHSA's policies are expected to further expand the market size of the pharmaceutical retail industry, benefiting leading retail chain enterprises[161]. - The government aims to cultivate 1-3 large-scale digital and comprehensive pharmaceutical distribution enterprises with revenues exceeding 500 billion yuan by 2025, presenting growth opportunities for leading companies like the one in focus[187]. Logistics and Supply Chain - The company has established a nationwide intelligent pharmaceutical logistics network covering 96% of regions, with a total warehouse area exceeding 3.95 million square meters, including 2.55 million square meters of GSP-certified pharmaceutical warehouses[128]. - The company has developed a differentiated logistics structure, deploying "Bb integrated warehouses" in 24 core hubs to enhance supply chain efficiency for both B-end and C-end customers[128]. - The company has formed strategic partnerships with over 30 domestic and foreign pharmaceutical companies, enhancing its distribution and logistics capabilities[131][132]. Product and Service Development - The company has established a comprehensive new product strategy framework, integrating business development, research, and marketing[78]. - The company aims to enhance its commercialization capabilities and establish a comprehensive promotion network to improve core competitiveness[80]. - The company has built a professional product promotion team and obtained agency qualifications for several key brands, enhancing its market presence[124]. REITs and Financial Instruments - The company successfully issued public REITs, raising CNY 1.158 billion with a subscription multiple of 1,192 times, marking a record in public REITs issuance history[7]. - The public REITs project has a base asset in Wuhan, recognized as one of the top ten "National Intelligent Warehousing and Logistics Demonstration Bases" by the National Development and Reform Commission, with a building area of approximately 172,000 square meters[15]. - The rapid development of public REITs in China's infrastructure sector since the first batch of 9 REITs launched in 2021 highlights significant market potential[178].

证券代码：600998 证券简称：九州通 公告编号：临 2025-023 表决结果：同意 12 票，反对 0 票，弃权 0 票。 该议案尚需提交公司股东会审议批准。 详见公司同日披露的 2024 年度独立董事述职报告。 1 九州通医药集团股份有限公司 第六届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 4 月 26 日，九州通医药集团股份有限公司（以下简称"九州通"或 "公司"）召开第六届董事会第十四次会议，本次会议以现场结合通讯的方式召 开，根据公司《董事会议事规则》的相关规定，会议通知已于 2025 年 4 月 7 日 以电话、邮件、微信等方式通知全体董事。本次会议应到董事 12 人，实到 12 人， 会议由董事长刘长云先生主持。公司监事和高级管理人员列席了会议。本次会议 的召集和召开程序符合《公司法》及《公司章程》等相关规定。 经过审议并表决，本次会议通过了以下议案： 一、《关于公司 2024 年度总经理工作报告的议案》 表决结果：同意 12 票，反对 0 票，弃权 0 票。 ...

每股分配比例：每10股派发现金红利2.00元（含税），本年度不进行资 本公积金转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本扣除回购专户股 份为基数，具体日期将在权益分派实施公告中明确。 如在股权登记日前公司总股本发生变动，公司拟维持每股分配比例不变， 相应调整分配总额，并将在相关公告中披露。 证券代码：600998 证券简称：九州通 公告编号：临 2025-022 九州通医药集团股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （二）公司2024年度利润分配预案不触及其他风险警示情形 公司不触及《上海证券交易所股票上市规则（2025年4月修订）》第9.8.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 一、2024年度利润分配预案内容 （一）利润分配预案的具体内容 经中审众环会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日， 九州通医药集团股份有限公司（以下简称"公司"）母公司报表中期末未分配利 润 ...